Economic Modelling

We tailor economic models to the treatment or pathway under investigation. While Cost-Effectiveness Analyses (CEAs) can be useful for comparing similar treatments, they are less effective when evaluating novel therapeutics or pathways. Our approach ensures models are customised to the specific disease or intervention, providing actionable insights for decision-making.​

At Zeumed, we collaborate with both payers and life science organizations to develop customised Value-Based Pricing (VBP) models. Using econometric techniques including Synthetic Control Methods, we design robust frameworks tailored to the intervention, carefully selecting outcome measures that matter most to payers and providers, ensuring decisions are backed by strong, evidence-based insights.

​

Without expert input, organisations risk developing incomplete or biased models that fail to capture the true value of an intervention. This can lead to poor funding decisions, wasted resources, or undervalued innovations. Our expertise ensures that every model is rigorous, evidence-based, and aligned with payer expectations, helping to secure sustainable reimbursement outcomes.